Across TCGA pan-cancer cohorts, IGHG2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated IGHG2 data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher IGHG2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated IGHG2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and GBM show a favorable association.

HNSC, UCEC, and GBM are the cancer types where IGHG2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	III,IV	0.870	0.705	.014	25	view →
UCEC	DFS	Tertile	All	0.818	0.945	.028	10	view →
GBM	DFS	Tertile	All	0.491	0.195	.020	8	view →
CCRCC	DFS	Median	III,IV	0.848	0.577	.021	5	view →
LUAD	OS	Tertile	All	0.874	1.000	.019	3	view →
LSCC	DFS	Median	All	0.908	0.962	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

Exploration

Same gene, other analysis: IGHG2 tumor-vs-normal RNA expression · all IGHG2 data types